Literature DB >> 25160120

Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.

Devon S Conway1, Jeffrey A Cohen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25160120     DOI： 10.1177/1352458514535283

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  1 in total

1.  The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Dimitris Mavridis; Nikolaos Grigoriadis; Efthymios Dardiotis; Ioannis Heliopoulos; Panagiotis Papathanasopoulos; Theodoros Karapanayiotides; Constantinos Kilidireas; Georgios M Hadjigeorgiou; Konstantinos Voumvourakis
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.